![Ofer Shpilberg](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ofer Shpilberg
Corporate Officer/Principal bei Dynamix Pharmaceuticals Ltd.
Aktive Positionen von Ofer Shpilberg
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Dynamix Pharmaceuticals Ltd.
![]() Dynamix Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Dynamix Pharmaceuticals Ltd. discovers and develops small-molecule drugs for treating cancer and autoimmune disorders. It focuses its discovery on cancer metabolism modulators and type II selective kinase inhibitors. The firm offers DNX-03000 that targets Pyruvate Kinase M2 (PKM2), an enzyme that is a key mediator of cancer metabolism; and DNX-06000 that targets an undisclosed target. The company was founded by Oren M. Becker in 2009 and is headquartered in Rehovot, Israel. | Corporate Officer/Principal | - | - |
Karriereverlauf von Ofer Shpilberg
Statistik
International
Israel | 2 |
Operativ
Corporate Officer/Principal | 1 |
Sektoral
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Dynamix Pharmaceuticals Ltd.
![]() Dynamix Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Dynamix Pharmaceuticals Ltd. discovers and develops small-molecule drugs for treating cancer and autoimmune disorders. It focuses its discovery on cancer metabolism modulators and type II selective kinase inhibitors. The firm offers DNX-03000 that targets Pyruvate Kinase M2 (PKM2), an enzyme that is a key mediator of cancer metabolism; and DNX-06000 that targets an undisclosed target. The company was founded by Oren M. Becker in 2009 and is headquartered in Rehovot, Israel. | Health Technology |
- Börse
- Insiders
- Ofer Shpilberg
- Erfahrung